Sandbox/22

{====Stage C====

Treatment goal: ❑
❑ Diuretic therapy for fluid retention ❑ ACE inhibitors (Class I, level of evidence A) ❑ Angiotensin II receptor blocker (ARBs), use in: ❑ ACE inhibitor intolerant patients with reduced LVEF (Class I, level of evidence A) ❑ As an alternative to ACE inhibitor as first line therapy (Class IIa, level of evidence A) ❑ Beta blockers (for all stable patients) (Class I, level of evidence A) ❑ Aldosterone receptor antagonist ❑ NYHA class II-IV with LVEF ≤ 35% (Class I, level of evidence A) ❑ Hydralazine and isosorbide dinitrate ❑ ❑ ❑ Digoxin ❑ ❑ Omega-3 fatty acid ❑ Implantable cardioverter defibrillator (ICD) to prevent sudden death in: ❑ ❑ ❑ ❑ ❑ Cardiac resynchronization therapy (CRT) ❑ ❑ ❑ ❑